Cargando…
A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations
BACKGROUND: A reported clinical pharmacokinetics and safety study of suspension formulation of ensitrelvir, a therapeutic agent used in severe acute respiratory syndrome coronavirus 2 infection, demonstrated favorable pharmacokinetics and was well tolerated in healthy male Japanese and White partici...
Autores principales: | Shimizu, Ryosuke, Sonoyama, Takuhiro, Fukuhara, Takahiro, Kuwata, Aya, Matsuo, Yumiko, Kubota, Ryuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575992/ https://www.ncbi.nlm.nih.gov/pubmed/37798608 http://dx.doi.org/10.1007/s40261-023-01309-z |
Ejemplares similares
-
Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults
por: Shimizu, Ryosuke, et al.
Publicado: (2022) -
Evaluation of the Drug–Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults
por: Shimizu, Ryosuke, et al.
Publicado: (2023) -
Pharmacokinetics, safety, and tolerability of single and multiple doses of zuranolone in Japanese and White healthy subjects: A phase 1 clinical trial
por: Sonoyama, Takuhiro, et al.
Publicado: (2023) -
530. Population Pharmacokinetic Analysis of Ensitrelvir, an Inhibitor of 3C-like (3CL) Protease of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) for patients with SARS-Cov-2 Infection
por: Ishibashi, Toru, et al.
Publicado: (2023) -
548. Combined Results of the Phase 2a/2b/3 Randomized Controlled Trials of Ensitrelvir for the Treatment of COVID-19 Infection
por: Tsuge, Yuko, et al.
Publicado: (2023)